TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
Tatiana Erazo(Memorial Sloan Kettering Cancer Center), Michael G. Kharas(Memorial Sloan Kettering Cancer Center)
Cited by 28
Related Papers
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
|Nature Communications|2019|146
HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
|Nature Communications|2020|72
RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells
|Nature Communications|2023|20
SON is an essential m6A target for hematopoietic stem cell fate
|Cell stem cell|2023|17
Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia
|bioRxiv (Cold Spring Harbor Laboratory)|2018|14